Duracar CAR-T cells therapy(Regen Biopharma Inc)

N/A

Report date: 2024/09/24 10:49:38

Base Information

Drug NameDuracar CAR-T cells therapy(Regen Biopharma Inc)
Drug Alias NameDuraCAR CAR T cells therapy(Regen Biopharma Inc)tCellVax (Regen Biopharma Inc)Ex-vivo siRNA NR2F6 (Regen Biopharma Inc)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionNR2F6 protein inhibitorsB-lymphocyte antigen CD19 modulators
TargetsNR2F6 proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegen Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegen Biopharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A